1. Resources and Training
  2. Cardio-Metabolic
  3. Product resources and training
  4. ENTRESTO® (sacubitril/valsartan) resources
  5. Media library
  6. PCCS Conference 2021 – Novartis symposium recording

Prescribing information

 

PCCS Conference 2021 – Novartis symposium recording

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Watch the video from the 2021 PCCS Conference: ‘Addressing health inequalities in Heart Failure: a real world case study’.

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HFrEF, heart failure with reduced ejection fraction.

 

Reference

  1. Entresto Summary of Product Characteristics, 2021. 
Rate this content: 
No votes yet
UK | December 2021 | 165125
Cardio-metabolic
Article
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]